Bright Green
Bright Green Corporation is a DEA-approved, publicly traded U.S. company specializing in the manufacturing of plant-based drugs and APIs, with a focus on reducing dependency on foreign imports through sustainable practices and advanced research facilities.
Overview of Bright Green Corporation
Bright Green Corporation is a DEA-approved company and a pioneer in the 'Drugs Made in America' movement. It is a licensed manufacturer of plant-based drugs and Active Pharmaceutical Ingredients (APIs) in the U.S. Bright Green is the first publicly traded company in the U.S. to receive DEA federal authorization for the growth, manufacturing, and sale of cannabis and related products for pharmaceutical applications and research. The company is headquartered at 401 E Las Olas Blvd #1400, Fort Lauderdale, Florida, with an Agricultural and Operations Center in Grants, New Mexico.
Manufacturing and Supply Division
Bright Green Corporation's plant-based drug manufacturing and supply division focuses on producing a wide range of medications derived from plant-based drugs. This division adheres to stringent quality control standards and Good Manufacturing Practices (GMP). It maintains strict control over its supply chain to ensure product integrity and traceability. The company is committed to compliance, innovation, and patient safety, and emphasizes ongoing research and development efforts to enhance the efficacy, safety, and accessibility of its plant-based medications.
Research and Development Efforts
Bright Green Corporation's Research and Development division is headquartered in Grants, New Mexico, within a 1 million+ square foot facility. The R&D division focuses on botanical drug discovery and innovation, including Schedule I and Schedule II plant-based drugs. The division adheres to strict regulatory standards and compliance protocols and plans to deploy comprehensive clinical trials to evaluate the safety and efficacy of its botanical medications. Bright Green also collaborates with leading academic institutions, research organizations, and industry partners to accelerate R&D efforts.
Cannabinoid Production and Distribution
Bright Green Corporation's cannabinoid production and distribution division uses advanced systems to optimize efficiency and quality. This includes tissue culture propagation to produce consistent crops and innovations in plant cultivation to enhance greenhouse conditions sustainably. The division also uses automation technology to streamline production, improving efficiency and accuracy. Bright Green aims to ensure high standards of quality and consistency in its cannabinoid products.
Partnerships and Initiatives
Bright Green Corporation has several strategic partnerships and initiatives. The company has partnered with One Tree Planted to commit to planting 5,000 trees over the next year as part of its sustainable manufacturing practices. Additionally, Bright Green has launched a USCIS EB-5 program in partnership with Asia Capital Pioneers Group (ACPG) to raise $500 million for the expansion of their high-security, advanced glass Greenhouse facilities. The company is dedicated to securing long-term federal government contracts to establish a reliable domestic API supply chain and reduce U.S. dependency on foreign drug imports.